Laboratory information management system GoMeyra LIMS reported on Thursday the launch of the revolutionary new tech solution that triples daily testing capacity and provides test results within hours for medical laboratories and practices.
A Silicon Valley visionary and experienced systems IT developer created GoMeyra during the COVID-19 lockdown to address the testing crisis created by the pandemic, which exposed the drawbacks of antiquated systems and workforce shortages at labs across the country.
According to the company, its cloud-based solution enables unprecedented COVID-19 processing times for PCR, rapid antigen and antibody testing, as well as vaccine monitoring. It serves as the end-to-end processing platform for US labs, medical providers, contractors, corporations, universities, casinos, live entertainment productions and professional sporting events to handle large-scale testing, help control the coronavirus outbreak as well as get more Americans back to work, school, travel and normal activities.
The medical practice clients powered by GoMeyra LIMS include University of South Carolina in Columbia, SC, handling on-campus rapid testing; COVID Testing LLC in Orlando, managing student testing for the University of Central Florida; American Molecular Laboratories in Chicago; Millenia Advanced Scientific in Orlando, Vital Medical Diagnostics Inc in Houston; and Vitae Diagnostics in Southern California.
Merck launches Phase 3 trial for dengue vaccine candidate V181
BioNet and Bio Farma sign MoU on TdaP vaccine
Dx&Vx accelerates universal COVID-19 vaccine development
Moderna withdraws application for flu-COVID combination vaccine pending additional efficacy data
CTP delivers 18,000 sqm Serbian facility for SCHOTT Pharma to support global expansion
LakeShore Biopharma launches novel packaging solution for YSJA rabies vaccine (Vero cell)
Scancell partners with NHS Cancer Vaccine Launch Pad to accelerate melanoma trial recruitment
Orexo reports positive results for powder-based intranasal vaccine using AmorphOX technology
GC Biopharma's BARYTHRAX receives Korean regulatory approval
GSK grants USD2m to boost adult vaccination efforts
Valneva and LimmaTech begin Phase 2 infant trial for Shigella vaccine candidate S4V2
Circio Holding and Entos Pharmaceuticals collaborate on circular RNA delivery
AKAGERA Medicines completes first cohort in phase 1 SAD/MAD study of AKG-100